20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Alto Neuroscience, Inc. (ANRO) operates in the BIOTECHNOLOGY industry and is headquartered in Mountain View, United States with about 68 employees. Its market capitalization is roughly $1 billion. In the fiscal year ended 2025-09-30, ANRO reported $0M in revenue and ($63M) in net income.
Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States. The company's product pipeline includes ALTO-100, which is in Phase 2b clinical trial for the treatment of patients with bipolar depression (BPD).
Interactive charts & full statements →
| Income statement | TTM → 2026-06-30 | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 | 2021-09-30 |
|---|---|---|---|---|---|---|
| Total Revenue | $0M | $0M | $0M | $0M | $0M | $0M |
| Gross Profit | — | ($1M) | ($1M) | $0M | $0M | $0M |
| Gross Margin % | — | — | — | — | — | 30.9% |
| Operating Income (EBIT) | $44M | ($66M) | ($69M) | ($38M) | ($29M) | ($12M) |
| Operating Margin % | — | — | — | — | — | -5740.9% |
| Net Income | ($84M) | ($63M) | ($61M) | ($36M) | ($28M) | ($9M) |
| Net Margin % | — | — | — | — | — | -4374.8% |
| EBITDA | ($81M) | ($60M) | ($62M) | ($35M) | ($27M) | ($9M) |
| Earnings Per Share (EPS) | $-2.47 | $-2.19 | $-2.50 | $-1.35 | $-1.08 | $-0.36 |
| Shares Outstanding (M) | 43M | 29M | 25M | 27M | 26M | 26M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | $0M | $0M | $0M | $0M | $0M | $0M | $0M | $0M |
| Gross Profit | — | $0M | $0M | $0M | $0M | $0M | $0M | $0M |
| Gross Margin % | — | — | — | — | — | — | -43.1% | — |
| Operating Income (EBIT) | ($29M) | ($27M) | $116M | ($15M) | ($19M) | ($16M) | ($17M) | ($19M) |
| Operating Margin % | — | — | — | — | — | — | -4314.0% | — |
| Net Income | ($28M) | ($26M) | ($16M) | ($14M) | ($18M) | ($15M) | ($15M) | ($17M) |
| Net Margin % | — | — | — | — | — | — | -3858.1% | — |
| EBITDA | ($27M) | ($26M) | ($15M) | ($13M) | ($17M) | ($14M) | ($15M) | ($16M) |
| Earnings Per Share (EPS) | $-0.65 | $-0.80 | $-0.51 | $-0.52 | $-0.65 | $-0.56 | $-0.56 | $-0.62 |
| Shares Outstanding (M) | 43M | 33M | 32M | 27M | 27M | 27M | 27M | 27M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Cash flow | TTM → 2026-06-30 | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 | 2021-09-30 |
|---|---|---|---|---|---|---|
| Cash from Operations (CFO) | ($68M) | ($52M) | ($47M) | ($33M) | ($20M) | ($9M) |
| Capital Expenditures (CapEx) | $1M | $0M | $2M | $0M | $1M | $1M |
| Free Cash Flow (FCF) | ($69M) | ($52M) | ($49M) | ($34M) | ($21M) | ($10M) |
| FCF Margin % | — | — | — | — | — | -4734.3% |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly cash flow | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Cash from Operations (CFO) | ($20M) | ($27M) | ($12M) | ($10M) | ($14M) | ($17M) | ($13M) | ($12M) |
| Capital Expenditures (CapEx) | $0M | $1M | $0M | $0M | $0M | $0M | $1M | $1M |
| Free Cash Flow (FCF) | ($20M) | ($28M) | ($12M) | ($10M) | ($14M) | ($17M) | ($14M) | ($13M) |
| FCF Margin % | — | — | — | — | — | — | -3433.3% | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2026-06-30 | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 | 2021-09-30 |
|---|---|---|---|---|---|---|
| Total Assets | $254M | $185M | $178M | $87M | $51M | $29M |
| Cash & Cash Equivalents | $244M | $176M | $168M | $83M | $48M | $26M |
| Total Liabilities | $35M | $34M | $26M | $158M | $89M | $41M |
| Total Debt (Short + Long-Term) | $19M | $19M | $12M | $10M | $10M | $0M |
| Total Shareholders' Equity | $219M | $151M | $151M | ($72M) | ($38M) | ($12M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive ANRO viewer.
About TickerBase · Data methodology & sources · Privacy · Terms